Engage Therapeutics Doses First Patient in Phase 2b Trial of Epilepsy Seizure Rescue Therapy Staccato® Alprazolam

Engage Therapeutics Announces $23 Million Series A Financing to Advance Phase 2b Development of Novel Epileptic Seizure Rescue Therapy
April 20, 2018
STACCATO® ALPRAZOLAM
May 18, 2018

Peachtree BioResearch Solutions to Execute Multi-Center Trial

SUMMIT, N.J. – April XX, 2018 – Engage Therapeutics, Inc., today announced dosing of the first patient in its multi-center, double-blind, randomized Phase 2b StATES (Staccato® Alprazolam Terminates Epileptic Seizures) trial to investigate the safety and efficacy of Staccato alprazolam in subjects with epilepsy that have a predictable seizure pattern.

The StATES trial (NCT03478982) will enroll 108 patients across 40 U.S.-based clinical sites. The primary endpoint is the cessation of seizure activity. Seizure episode severity and the use of a rescue medication, as well as the incidence of adverse events will also be evaluated. Topline data is expected in the second half of 2019. Staccato alprazolam, a single use, investigational epileptic seizure rescue therapy, combines the Staccato delivery technology, which is currently used in a U.S. Food and Drug Administration (FDA) –approved product, with alprazolam, an FDA-approved benzodiazepine.

Greg Mayes, president, CEO and founder of Engage Therapeutics, said, “For individuals with epilepsy that have a predictable seizure pattern, currently available rescue treatments can only address the prevention of seizure activity once the first seizure ends, but Staccato alprazolam has the potential to be the first and only product that can abort an active seizure. We are excited by the enthusiastic response that this study has received from the epilepsy community and how quickly we have been able to advance this promising candidate to this point in development.”

 

Kristy Nichols, president and co-founder of Peachtree, added, “Engage is the type of client we seek – an emerging CNS focused company with a novel therapy that addresses a significant unmet medical need. We are confident that our deep clinical trial management experience for CNS disorders and our demonstrated passion for partnership will result in a mutually successful outcome.”

About Engage Therapeutics, Inc.

Engage Therapeutics is developing Staccato alprazolam, for the cessation of active and acute epileptic seizures.  The investigational product is a small, easy-to-use hand-held drug-device combination that leverages a fast acting delivery system already used in an FDA-approved product with FDA-approved alprazolam.  Staccato alprazolam demonstrated reduction of seizure-like activity in a photosensitivity model in a Phase 2a proof of concept study. The product has now proceeded into a Phase 2b study known as the StATES trial.  Engage Therapeutics is based in Summit, N.J.  For additional information please see www.EngageTherapeutics.com.

 

About Peachtree
Entering its 10th year, Peachtree BioResearch Solutions, Inc. is a Clinical Research Organization that specializes in providing clinical development services for emerging to mid-sized biotechnology, pharmaceutical, and medical device companies. With a highly-experienced clinical development team, Peachtree offers Clinical Project Management, Clinical Monitoring, Medical Monitoring, Biometrics (data management and statistical analysis), Technical Report Writing, Quality Assurance, and Clinical Staff Resourcing. Starting with one client at inception, Peachtree has grown its portfolio to over 65 clients providing services ranging from niche projects to full support. For additional information, visit www.peachtreebrs.com.

 

Media Contact

XXXX

Engage Therapeutics

 

John Durkee

Peachtree BioResearch Solutions